# Clinical Trials Summary: Lithium for Alzheimer's Disease

## Overview of Human Trial Evidence

This document summarizes all randomized controlled trials (RCTs) evaluating lithium for cognitive impairment and Alzheimer's disease.

---

## Completed Trials

### 1. Nunes et al. (2013) - Microdose Lithium

| Parameter | Details |
| --------- | ------- |
| **Citation** | Nunes MA, Viel TA, Buck HS. *Curr Alzheimer Res*. 2013 Jan;10(1):104-7 |
| **PMID** | [22746245](https://pubmed.ncbi.nlm.nih.gov/22746245/) |
| **Design** | Randomized, double-blind, placebo-controlled |
| **Population** | Patients with AD |
| **N** | 40 |
| **Duration** | 15 months |
| **Intervention** | Microdose lithium carbonate (300 µg/day) |
| **Primary Outcome** | Cognitive function (MMSE) |
| **Result** | **Positive** - Stabilized cognitive impairment |
| **Key Finding** | Cognitive stabilization with extremely low doses |

---

### 2. Forlenza et al. (2019) - MCI Trial

| Parameter | Details |
| --------- | ------- |
| **Citation** | Forlenza OV, Radanovic M, Talib LL, Gattaz WF. *Br J Psychiatry*. 2019 Nov;215(5):668-674 |
| **PMID** | [30947755](https://pubmed.ncbi.nlm.nih.gov/30947755/) |
| **Registry** | [NCT01055392](https://clinicaltrials.gov/show/NCT01055392) |
| **Design** | Randomized, double-blind, placebo-controlled |
| **Population** | Older adults with amnestic MCI |
| **N** | 61 |
| **Duration** | 2 years (double-blind) + 24 months (single-blind follow-up) |
| **Intervention** | Lithium carbonate (target 0.25-0.5 mEq/L) |
| **Primary Outcomes** | ADAS-cog, CDR-SB |
| **Results** | **Positive** - See table below |

#### Detailed Results

| Outcome | Placebo | Lithium | Significance |
| ------- | ------- | ------- | ------------ |
| Cognitive function (24 mo) | Declined | **Stable** | Yes |
| Functional status (24 mo) | Declined | **Stable** | Yes |
| Memory tests (24 mo) | Worsened | **Improved** | Yes |
| Attention tests (24 mo) | Worsened | **Improved** | Yes |
| CSF Aβ1-42 (36 mo) | — | **Increased** | Yes |
| Conversion to dementia (48 mo) | Higher | Lower | Trend |

#### Conclusion

> "Long-term lithium attenuates cognitive and functional decline in amnestic MCI, and modifies Alzheimer's disease-related CSF biomarkers."

---

### 3. Hampel et al. (2009) - Short-Term Trial

| Parameter | Details |
| --------- | ------- |
| **Citation** | Hampel H, Ewers M, Bürger K, et al. *J Clin Psychiatry*. 2009 Jun;70(6):922-31 |
| **PMID** | [19573486](https://pubmed.ncbi.nlm.nih.gov/19573486/) |
| **Design** | Randomized, single-blind, placebo-controlled, multicenter |
| **Population** | Patients with mild AD |
| **N** | 71 |
| **Duration** | 10 weeks |
| **Intervention** | Lithium (target 0.5-0.8 mEq/L) |
| **Primary Outcome** | Cognitive function (ADAS-cog) |
| **Result** | **Negative** - No significant cognitive benefit |
| **CSF Biomarkers** | p-tau decreased significantly in lithium group |

#### Why Negative?

- Very short duration (10 weeks)
- May have been insufficient for cognitive effects
- Biomarker changes suggest biological activity was present

---

### 4. Devanand et al. (2022) - Lit-AD Trial (Behavioral)

| Parameter | Details |
| --------- | ------- |
| **Citation** | Devanand DP, et al. *Am J Geriatr Psychiatry*. 2022 Jan;30(1):32-42 |
| **PMID** | [34059401](https://pubmed.ncbi.nlm.nih.gov/34059401/) |
| **Design** | Randomized, double-blind, placebo-controlled, 4-site |
| **Population** | AD patients with agitation/aggression |
| **N** | 80 |
| **Duration** | 12 weeks |
| **Intervention** | Low-dose lithium |
| **Primary Outcome** | Agitation (NPI) |
| **Result** | **Negative** - No significant improvement in agitation |
| **Note** | This trial focused on behavioral symptoms, not cognition |

---

## Meta-Analyses

### Matsunaga et al. (2015)

| Parameter | Details |
| --------- | ------- |
| **Citation** | *J Alzheimers Dis*. 2015;48(2):403-10 |
| **PMID** | [26402004](https://pubmed.ncbi.nlm.nih.gov/26402004/) |
| **Trials Included** | 3 RCTs |
| **Total N** | 232 |
| **Primary Outcome** | Cognition (ADAS-cog or MMSE) |

#### Matsunaga Results

- **SMD**: -0.41 (favoring lithium)
- **95% CI**: -0.81 to -0.02
- **p-value**: 0.04 (statistically significant)
- **Heterogeneity**: I² = 47% (moderate)

**Conclusion**: Lithium treatment may have beneficial effects on cognitive performance in subjects with MCI and AD dementia.

---

### Terao & Kodama (2024) - Network Meta-Analysis

| Parameter | Details |
| --------- | ------- |
| **Citation** | *Ageing Res Rev*. 2024 Feb;94:102203 |
| **PMID** | [38253184](https://pubmed.ncbi.nlm.nih.gov/38253184/) |
| **Comparators** | Lithium, donanemab, lecanemab, aducanumab |
| **Trials Included** | 8 RCTs |
| **Total N** | 6,547 |

#### Terao Results

| Outcome | Finding |
| ------- | ------- |
| MMSE efficacy | Lithium > donanemab > aducanumab > placebo |
| ADAS-cog efficacy | All drugs > placebo |
| Tolerability | Lithium > placebo; antibodies < placebo |
| Acceptability | Lithium = placebo; antibodies < placebo |

**Conclusion**: Low-dose lithium may be safer than aducanumab, lecanemab and donanemab, and may be more effective than aducanumab.

---

## Pending/Planned Trials

### LATTICE Trial (Published 2025 - Results Forthcoming)

| Parameter | Details |
| --------- | ------- |
| **Full Name** | Lithium as a Treatment to Prevent Impairment of Cognition in Elders |
| **Citation** | Gildengers AG, et al. *Alzheimers Dement (N Y)*. 2025 Jun 11;11(2):e70112 |
| **PMID** | [40501510](https://pubmed.ncbi.nlm.nih.gov/40501510/) |
| **Registry** | [NCT03185208](https://clinicaltrials.gov/show/NCT03185208) |
| **Location** | University of Pittsburgh |
| **Design** | Double-blind, placebo-controlled RCT |
| **Population** | Adults ≥60 years with MCI |
| **N** | 80 enrolled |
| **Duration** | 2 years follow-up |
| **Imaging** | 7T MRI + PET for amyloid-β and tau |
| **Biomarkers** | Plasma-based |
| **Status** | Completed enrollment; **RESULTS FORTHCOMING** |

#### LATTICE Baseline Characteristics

| Metric | Value |
| ------ | ----- |
| Mean age | 72 (SD 7.7) years |
| Male/Female | 35/45 |
| PET imaging completed | 75/80 |
| 7T MRI completed | 66/80 |
| Amyloid-β positive | 21 (28%) |
| Amyloid-β negative | 54 (72%) |

**Significance**: This is the most rigorous ongoing RCT of lithium for MCI, with advanced imaging and biomarkers. Results are expected to provide definitive evidence.

---

### Lithium Orotate Trial (Planned)

| Parameter | Details |
| --------- | ------- |
| **Lead Investigator** | Dr. Bruce Yankner, Harvard Medical School |
| **Formulation** | Lithium orotate (first human trial of this form for AD) |
| **Population** | TBD |
| **Status** | Planned (as of August 2025) |
| **Significance** | First trial to test the superior formulation identified in Nature 2025 |

**Quote from Dr. Yankner:**
> "Before recommending lithium orotate, we need to determine the effective and safe dose range in people. We are planning a clinical trial of lithium orotate that will hopefully begin in the near future."

---

## Trial Limitations Summary

| Limitation | Impact |
| ---------- | ------ |
| **Small sample sizes** | Wide confidence intervals, limited power |
| **Short durations** | May miss long-term effects |
| **Lithium carbonate only** | Orotate form never tested in humans for AD |
| **Variable dosing** | Difficult to identify optimal dose |
| **Heterogeneous populations** | MCI vs. AD, different stages |
| **No Phase 3 trials** | Not sufficient for FDA approval |

---

## What Would a Definitive Trial Look Like?

### Proposed Design (Based on Nature 2025)

| Parameter | Recommendation |
| --------- | -------------- |
| **Population** | MCI or asymptomatic high-risk (APOE4+, biomarker+) |
| **Intervention** | Lithium orotate (dose TBD based on PK study) |
| **Comparator** | Placebo |
| **Duration** | 2-3 years minimum |
| **Primary Outcome** | Cognitive composite + biomarkers |
| **Biomarkers** | p-tau217, amyloid PET, brain aging clocks |
| **N** | 300-500 for adequate power |
| **Safety Monitoring** | Renal function, thyroid, cardiac |

---

**Last Updated:** February 5, 2026
